Review highlights pharmacokinetic aspects of antibody-based therapeutics in autoimmune disorders, suggesting that absorption and distribution are key to therapeutic efficacy.
Antibody-based therapeutics are specifically designed to bind to antigens, thereby facilitating the treatment of various diseases, including tumors and autoimmune disorders, resulting in significant therapeutic effects. Notably, the therapeutic efficacy of antibody-based therapeutics is contingent upon their in vivo processes. This article provides a review of the pharmacokinetic and biological analysis methods on antibody-based therapeutics, encompassing their absorption, distribution, and elimination within the organism. The analysis reveals that antibody-based therapeutics are predominantly administered intravenously or subcutaneously and undergo distribution within organs primarily through convection. The principal mechanisms for drug clearance include targeted clearance and endocytosis. Furthermore, many antibody-based therapeutic formulations are implantations of strategies aimed at extending their half-lives. These critical findings offer valuable insights and foundational knowledge for the research and development of the in vivo processes related to antibody-based therapeutics.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: